CRISPR newco Intellia gets $15M from Atlas, Novartis

Intellia Therapeutics Inc. (Cambridge, Mass.) closed a $15 million series A round from Atlas Venture and Novartis AG (NYSE:NVS; SIX:NOVN) to develop therapeutics using CRISPR-Cas9 technology.

Intellia is developing ex vivo therapies in which cells are modified genetically and returned to the patient, including regulation of chimeric antigen receptors on T cells (CAR-T) and checkpoint inhibitors. It is also developing in vivo therapeutics to address ophthalmic, central nervous system, muscle, liver and infectious diseases. ...